Liquid Biopsy For Cancer Diagnostics Market Report 2026

Liquid Biopsy For Cancer Diagnostics Market Overview

• Liquid Biopsy For Cancer Diagnostics market size has reached to $10.75 billion in 2025 • Expected to grow to $22.99 billion in 2030 at a compound annual growth rate (CAGR) of 16.4% • Growth Driver: Rising Tide Of Cancer Is Anticipated To Fuels The Liquid Biopsy For Cancer Diagnostics Market Growth • Market Trend: Innovative Liquid Biopsy Solutions Revolutionizing Cancer Detection and Research • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Liquid Biopsy For Cancer Diagnostics Market?

Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient's blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics. The main types of liquid biopsy for cancer diagnostics include products and services. A product refers to any procedure, method, or tool created or used to identify a sickness or illness in people or other vertebrate animals. Various types of samples are involved, such as blood, urine, and saliva. The various types of cancer include lung cancer, breast cancer, colon cancer, and others, which are used by several end-users, including hospitals, diagnostic centers, and others.

What Is The Liquid Biopsy For Cancer Diagnostics Market Growth Forecast?

The liquid biopsy for cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $22.99 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to expansion of liquid biopsy in routine cancer screening, growing focus on personalized cancer care, increasing adoption in treatment response monitoring, rising investments in cancer diagnostics, expanding use in gastrointestinal and ovarian cancers. Major trends in the forecast period include growing adoption of liquid biopsy in lung cancer diagnosis, rising use of blood-based cancer screening methods, increasing demand for real-time cancer monitoring, expansion of liquid biopsy across multiple cancer types, rising clinical preference for minimally invasive diagnostics.

Global Liquid Biopsy For Cancer Diagnostics Market Segmentation

1) By Type: Product, Services 2) By Sample: Blood, Urine, Saliva 3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers 4) By End-User: Hospitals, Diagnostic Centers, Other End-Users Subsegments: 1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices 2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Is The Driver Of The Liquid Biopsy For Cancer Diagnostics Market?

The rising incidence of cancer is expected to propel the growth of the liquid biopsy for cancer diagnostics market going forward. Cancer is a broad category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Cancer increases the need for diagnostic procedures such as early cancer or tumor recurrence detection, risk assessment for each patient, and therapy monitoring to enable liquid biopsy to depict the full scope of the disease as tumor cells or tumor cell products are released from all metastatic or primary tumor sites, providing thorough and real-time information on tumor cell evolution, therapeutic targets, and mechanisms of therapy resistance. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, there were about 18.1 million cancer survivors in the United States. This figure is projected to rise to 22.5 million by 2032. By 2040, it's expected that the number of new cancer cases each year will reach 29.9 million, with cancer-related deaths estimated to increase to 15.3 million. Therefore, the rising incidence of cancer is driving the growth of the liquid biopsy for cancer diagnostics industry.

Key Players In The Global Liquid Biopsy For Cancer Diagnostics Market

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Global Liquid Biopsy For Cancer Diagnostics Market Trends and Insights

Major companies operating in the liquid biopsy for cancer diagnostics market are concentrating their efforts towards developing innovative solutions such as advanced liquid biopsy assays. An advanced liquid biopsy assay refers to a sophisticated and highly refined diagnostic test that analyzes various components present in a liquid biological sample, such as blood or other bodily fluids, to detect and characterize specific biomarkers associated with cancer or other diseases. For instance, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the launch of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. It is a research assay designed to facilitate noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. The TSO 500 ctDNA v2 assay is designed to simplify integration for users and enhance the depth of insights available for cancer research.

What Are Latest Mergers And Acquisitions In The Liquid Biopsy For Cancer Diagnostics Market?

In February 2024, Veracyte Inc., a US-based diagnostics company, acquired C2i Genomics Inc. for approximately US$70 million. With this acquisition, Veracyte aims to enhance its cancer-diagnostics platform by integrating C2i’s whole-genome minimal residual disease (MRD) detection technology to extend its reach across the cancer-care continuum, improve early detection and recurrence monitoring, and deliver deeper insights for clinicians and patients. C2i Genomics Inc. is a US-based biotechnology company that specializes in AI-enabled whole-genome MRD testing.

Regional Outlook

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Liquid Biopsy For Cancer Diagnostics Market?

The liquid biopsy for cancer diagnostics market includes revenues earned by entities by providing tumor detection, test validation, and clinical utility. The market value includes the value of related goods sold by the service provider or included within the service offering. The liquid biopsy for cancer diagnostics markets also includes sales of instruments, reagent kits, and liquid biopsy kits, which are used in providing liquid biopsy services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Liquid Biopsy For Cancer Diagnostics Market Report 2026?

The liquid biopsy for cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy for cancer diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.